Cambridge Heart inks development, distribution deal

Justine Varieur Cadet | | Cardiovascular Business | Heart Rhythm
Cambridge Heart has signed a non-exclusive development and distribution agreement with an undisclosed U.S. stress test manufacturer to develop a microvolt T-Wave alternans (MTWA) module.

The original equipment manufacturer MTWA module will be integrated into cardiac stress testing equipment to address sudden cardiac arrest prevention, according to the Bedford, Mass.-based Cambridge Heart.

The companies said that development of the module is anticipated to take nine to 15 months, based on production and regulatory approval timelines.

Justine Varieur Cadet

Related Content

Heart Rhythm Society legislative advocacy group raising funds for electrophysiology
FDA chooses not to approve new nasal spray for heart rhythm issues
Abbott gains CE mark approval for Volt PFA system
Enabling X-ray-free ablation procedures in the EP lab
The evolution of RF technology to reduce complications and improve outcomes
Abbott’s Amulet LAAO device linked to long-term safety, effectiveness

Around the web

Radiology Business
The impact of Trump tariffs on iodine contrast media costs

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.